Cantor Fitzgerald Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has initiated coverage on NeuroPace (NASDAQ:NPCE) with an Overweight rating and a price target of $11.
November 10, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroPace has received an Overweight rating from Cantor Fitzgerald, with a price target of $11.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for NeuroPace. The price target of $11 suggests potential upside for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100